Recurrent Breast Cancer Completed Phase 1 Trials for Trastuzumab (DB00072)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02060253Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast CancerTreatment
NCT00004074Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuTreatment
NCT00028535Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid TumorsTreatment